指南与共识介入腹部外周血管

活体肝移植后已确立的小肝综合征管理:药物、放射与外科干预:ILTS-iLDLT-LTSI 共识会议指南

Management of Established Small-for-size Syndrome in Post Living Donor Liver Transplantation: Medical, Radiological, and Surgical Interventions: Guidelines From the ILTS-iLDLT-LTSI Consensus Conference.
指南 / 共识 · Transplantation · 2023-09-25

该共识针对活体肝移植后已确立的小肝综合征(SFSS),指出门静脉过度灌注和内脏高动力循环是主要致病因素,管理按严重程度分层,初始以药物调节门静脉血流和支持治疗为主,药物失败或进展时考虑介入放射学和/或外科干预减少门静脉过度灌注,并给出了移植肝丢失高危的术后实验室阈值及再移植时机。

要点

  • 已确立 SFSS 初始治疗以药物调节门静脉血流并支持治疗为主,目标是促进移植肝再生和恢复。
  • 药物管理失败或病情进展至即将功能障碍甚至肝衰竭时,应考虑介入放射学和/或外科干预以减少门静脉过度灌注。
  • 术后第7天胆红素>10 mg/dL且INR>1.6,或术后第14天孤立性胆红素>20 mg/dL时,移植肝丢失风险急剧增加。

核心结论

  • 已确立 SFSS 的管理依据临床表现严重程度分层,初始聚焦药物调节门静脉血流和支持治疗以促进移植肝再生和恢复。
  • 药物管理失败或病情进展至即将功能障碍甚至肝衰竭时,应考虑介入放射学和/或外科干预减少门静脉过度灌注。
  • 多数患者经药物、介入放射学和/或外科管理获得良好结局并允许移植肝再生,但术后第7天胆红素>10 mg/dL且INR>1.6或术后第14天孤立性胆红素>20 mg/dL时移植肝丢失风险急剧增加。
  • 其他治疗失败时,应基于整体临床情况和上述术后实验室参数考虑再移植。

研究设计与样本

  • 该文件为 ILTS-iLDLT-LTSI 共识会议指南,针对活体肝移植后已确立 SFSS 的药物、放射与外科管理及再移植考虑和时机。

诊断标准与关键数值

  • 移植肝丢失风险急剧增加的术后实验室标准为:术后第7天胆红素>10 mg/dL且INR>1.6,或术后第14天孤立性胆红素>20 mg/dL。

临床应用与阅片要点

  • 已确立 SFSS 的初始管理以药物调节门静脉血流并给予支持治疗为主,目标是促进移植肝再生和恢复。
  • 药物管理失败或病情进展至即将功能障碍甚至肝衰竭时,应考虑介入放射学和/或外科干预以减少门静脉过度灌注。
  • 应关注术后第7天胆红素>10 mg/dL且INR>1.6或术后第14天孤立性胆红素>20 mg/dL,提示移植肝丢失风险急剧增加。
  • 其他治疗失败时,再移植应考虑基于整体临床情况和上述术后实验室参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Small-for-size syndrome (SFSS) following living donor liver transplantation is a complication that can lead to devastating outcomes such as prolonged poor graft function and possibly graft loss. Because of the concern about the syndrome, some transplants of mismatched grafts may not be performed. Portal hyperperfusion of a small graft and hyperdynamic splanchnic circulation are recognized as main pathogenic factors for the syndrome. Management of established SFSS is guided by the severity of the presentation with the initial focus on pharmacological therapy to modulate portal flow and provide supportive care to the patient with the goal of facilitating graft regeneration and recovery. When medical management fails or condition progresses with impending dysfunction or even liver failure, interventional radiology (IR) and/or surgical interventions to reduce portal overperfusion should be considered. Although most patients have good outcomes with medical, IR, and/or surgical management that allow graft regeneration, the risk of graft loss increases dramatically in the setting of bilirubin >10 mg/dL and INR>1.6 on postoperative day 7 or isolated bilirubin >20 mg/dL on postoperative day 14. Retransplantation should be considered based on the overall clinical situation and the above postoperative laboratory parameters. The following recommendations focus on medical and IR/surgical management of SFSS as well as considerations and timing of retransplantation when other therapies fail.

来源:Transplantation,查看原文。版权归原作者所有。

引用

  1. Kirchner VA, Shankar S, Victor DW, et al. Management of Established Small-for-size Syndrome in Post Living Donor Liver Transplantation: Medical, Radiological, and Surgical Interventions: Guidelines From the ILTS-iLDLT-LTSI Consensus Conference. Transplantation. 2023. PMID: 37749813. doi:10.1097/TP.0000000000004771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。